BREAST CANCER

The irreversible pan-HER tyrosine kinase inhibitor neratinib showed single-agent activity across cohorts of patients with <em>HER2</em>-mutant advanced cancers, according to findings from the phase II SUMMIT study presented at the 2017 AACR Annual Meeting.

Palbociclib (Ibrance) has been granted a full approval by the FDA for use in combination with letrozole as a frontline treatment for postmenopausal women with ER-positive, HER2-negative metastatic breast cancer.

The American Association for Cancer Research (AACR) will recognize several individuals for their contributions to cancer research during its annual meeting, to be held April 1 to 5 in Washington, DC.

Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, discusses novel agents for neoadjuvant triple-negative breast cancer (TNBC) treatment.

Adam M. Brufsky, MD, PhD, discusses considerations for using the bone-targeted agents denosumab and zoledronic acid in patients with breast cancer.

Leslie Schover, PhD, discusses ways in which providers can better address sexuality issues associated with treatment for patients with breast cancer.

Discussing the challenges that clinical practices will face as they implement the Medicare Oncology Care Model (OCM), the strategies that have worked for practices using similar payment models, and how the CMMI hope to work with oncologists for the success of the OCM.

Sara Hurvitz, MD, discusses&nbsp;ongoing advances that continue to revolutionize the treatment of patients with HER2+ breast cancer.

Giuseppe Curigliano, MD, PhD, discusses&nbsp;recent trials of immunotherapy and chemotherapy in triple-negative breast cancer, as well as the future role of immunotherapy in the treatment of breast cancer.

Progression-free survival was improved by adding abemaciclib to fulvestrant compared with fulvestrant alone in women with HR+/HER2-negative breast cancer enrolled in the phase III MONARCH 2 study.

According to a careful examination of studies exploring the immune response, immunotherapy will be most effective as a treatment for breast cancer when it is used to alter the tumor microenvironment. Nora Disis, MD, presented her findings during the 15th St. Gallen International Breast Cancer Conference.

Tari A. King, MD, discusses whether&nbsp;age is an independent prognostic factor in breast cancer or if it&#39;s simply a reflection of biology.

Inhibition of CDK4/6 results in improvements in progression-free survival in women with estrogen receptor ER-positive HER2-negative metastatic breast cancer whether it is endocrine sensitive or resistant.

Hope S. Rugo, MD, discusses efforts to find effective new treatments for triple-negative breast cancer.

Michael F. Press, MD, PhD, discusses&nbsp;the new ASCO-CAP guidelines for HER2 FISH testing.

During a presentation at the 2017 Miami Breast Cancer Conference,&nbsp;Leslie R. Schover, PhD, stressed the importance of preventive sexual counseling in reducing sexual dysfunction resulting from the treatment of breast cancer patients with aromatase inhibitors.

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses when to do a multiparameter genomic assay for patients with early-stage breast cancer.

Jubilee Brown, MD, obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.

The CDK 4/6 inhibitor&nbsp;ribociclib has been approved by the FDA for use in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with hormone-receptor&ndash;positive, HER2-negative advanced breast cancer.

Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, discusses how Medicare Access and CHIP Reauthorization Act affects breast cancer practice.

Sara A. Hurvitz, MD, discusses&nbsp;the pros and cons of anthracycline treatment.

Mohammad Jahanzeb, MD, discusses&nbsp;the designs of landmark trials in early HER2-positive targeted therapy and the adverse events associated with those treatments.

Joyce A. O&rsquo;Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, discusses the ongoing MONARCH and neoMONARCH studies in breast cancer.

According to a retrospective 4.5-year study of patients who had commercial and Medicare supplemental coverage, healthcare resource use and costs remain high among patients with metastatic triple-negative breast cancer.

Elizabeth A. Mittendorf, MD, PhD, discusses the immunotherapy combinations currently being investigated in the treatment of breast cancer.

Kimberly Blackwell, MD,&nbsp;discusses the results of the recent phase III OLYMPIAD trial, which showed olaparib (Lynparza) improved progression-free survival (PFS) versus standard chemotherapy in patients with <em>BRCA</em>-positive breast cancer.

Kelly K. Hunt, MD, professor of Surgery, and chair, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses incorporating biologic factors into breast cancer staging.

Hope Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses targeting the androgen receptor in breast cancer.

The addition of CDK4/6 and mTOR inhibitors to standard endocrine therapy has significantly improved outcomes in patients with hormone receptor (HR)&ndash;positive, HER2-negative advanced breast cancer.

Larry Norton, MD, says the so-called butterfly effect, in which a small creature can cause something on the scale of an earthquake merely by flapping its wings, is fodder for debate on whether the digital revolution in medicine can deliver on its promise for precision medicine.